在临床前模型中具有体内疗效的膀胱癌相关微小RNA
Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.
作者信息
Weidle Ulrich H, Birzele Fabian
机构信息
Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
Roche Pharma Research and Early Development, Pharmaceutical Sciences,Roche Innovation Center Basel, Basel, Switzerland.
出版信息
Cancer Diagn Progn. 2021 Jul 3;1(4):245-263. doi: 10.21873/cdp.10033. eCollection 2021 Sep-Oct.
Progressive and metastatic bladder cancer remain difficult to treat. In this review, we critique seven up-regulated and 25 down-regulated microRNAs in order to identify new therapeutic entities and corresponding targets. These microRNAs were selected with respect to their efficacy in bladder cancer-related preclinical in vivo models. MicroRNAs and related targets interfering with chemoresistance, cell-cycle, signaling, apoptosis, autophagy, transcription factor modulation, epigenetic modification and metabolism are described. In addition, we highlight microRNAs targeting transmembrane receptors and secreted factors. We discuss druggability issues for the identified targets.
进展期和转移性膀胱癌的治疗仍然困难。在本综述中，我们对7种上调和25种下调的微小RNA进行了分析，以确定新的治疗实体和相应靶点。这些微小RNA是根据它们在膀胱癌相关临床前体内模型中的功效来选择的。本文描述了干扰化疗耐药性、细胞周期、信号传导、细胞凋亡、自噬、转录因子调控、表观遗传修饰和代谢的微小RNA及其相关靶点。此外，我们重点介绍了靶向跨膜受体和分泌因子的微小RNA。我们还讨论了已确定靶点的成药问题。
Zotero 插件